ASCO: Adjuvant Bevacizumab Ups Survival in Cervical Cancer
Tuesday, June 4, 2013 (Last Updated: 06/05/2013)
TUESDAY, June 4 (HealthDay News) -- For women with chemotherapy-naive, recurrent, metastatic cervical cancer, treatment with chemotherapy plus bevacizumab is associated with improved survival, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.
Krishnansu Sujata Tewari, M.D., from the University of California Irvine in Orange, and colleagues conducted a four-arm study involving 452 women with recurrent metastatic cervical cancer, who were randomized to receive one of two chemotherapy regimens alone (cisplatin plus paclitaxel or topotecan plus paclitaxel) or chemotherapy plus bevacizumab.
The researchers observed no significant differences between the chemotherapy arms. For women receiving chemotherapy plus bevacizumab, the median overall survival was 17.0 months, versus 13.3 months for those receiving chemotherapy alone (hazard ratio, 0.71). The rates of tumor shrinkage were 48 percent for those who received chemotherapy plus bevacizumab and 36 percent for those who received chemotherapy alone (P = 0.0078).
"Women with advanced cervical cancer don't have many options. We finally have a drug that helps women live longer," Tewari said in a statement. "This is also possibly a first step toward turning cervical cancer into a chronic disease, helping women live longer and allowing time for additional treatments that could further slow the cancer's progression and improve survival"
Hematology & Oncology
OBGYN & Women's Health